1. Volume 86, Issue 6, Pages 1244-1252 (December 2014)
Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease 
Edwin M. Spithoven, Anneke Kramer, Esther Meijer, Bjarne Orskov, Christoph Wanner, Fergus Caskey, Frederic Collart, Patrik Finne, Damian G. Fogarty, Jaap W. Groothoff, Andries Hoitsma, Marie-Béatrice Nogier, Maurizio Postorino, Pietro Ravani, Oscar Zurriaga, Kitty J. Jager, Ron T. Gansevoort 
Kidney International 
Volume 86, Issue 6, Pages (December 2014)
DOI: /ki
Copyright © 2014 International Society of Nephrology Terms and Conditions

2. Figure 1
Incidence rate of renal replacement therapy (RRT) for autosomal dominant polycystic kidney disease (ADPKD) in member states of the EU27. Data are expressed per million population (p.m.p.) and adjusted for age and sex to the 2005 EU27 population. Data are the average values for the time period 2006–2010.
Kidney International  , DOI: ( /ki )
Copyright © 2014 International Society of Nephrology Terms and Conditions

3. Figure 2
Incidence rate of renal replacement therapy (RTT) for autosomal dominant polycystic kidney disease (ADPKD) per age group. Data are expressed per million of the age-related population (p.m.a.r.p.) and given for four consecutive study periods.
Kidney International  , DOI: ( /ki )
Copyright © 2014 International Society of Nephrology Terms and Conditions

4. Figure 3
Incidence rate of renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) versus non-ADPKD. Data are the average values during the time period 2006–2010 and expressed per million population (p.m.p.). The size of markers denotes the size of the population under study. AT, Austria; BE, Belgium; DK, Denmark; ES, Spain; ET, Estonia; FI, Finland; FR, France; GR, Greece; IT, Italy; LT, Latvia; NL, The Netherlands; PL, Poland; PO, Portugal; RO, Romania; SE, Sweden; SK, Slovakia; SL, Slovenia; UK, United Kingdom.
Kidney International  , DOI: ( /ki )
Copyright © 2014 International Society of Nephrology Terms and Conditions

5. Figure 4
Treatment modality at day 91 after starting renal replacement therapy comparing autosomal dominant polycystic kidney disease (ADPKD) patients with non-ADPKD patients. Patients on hemodialysis (upper panel), peritoneal dialysis (middle panel), and kidney transplant recipients (lower panel) as a percentage of the incident renal replacement therapy (RRT) population. Data are the average of the period 2006 through 2010 and adjusted for age and sex to the distribution of the EU27 population in The size of the marker denotes the size of the general population under study. AT, Austria; BE, Belgium; DK, Denmark; ES, Spain; FI, Finland; FR, France; GR, Greece; IT, Italy; NL, The Netherlands; RO, Romania; SE, Sweden; UK, United Kingdom.
Kidney International  , DOI: ( /ki )
Copyright © 2014 International Society of Nephrology Terms and Conditions